AnaBios is a preclinical contract research organization focused on translational research that measures drug activity directly in human tissue. The company primarily targets areas of high unmet medical need, including cardiac disease, lung disease, CNS disorders, pain, and itch. As a CRO it maintains an extensive network of hospitals and transplant centers to obtain ethically consented human tissue samples for ex vivo analysis. AnaBios announced a financing with Ampersand Capital Partners and said the funds will be used to strategically expand the business and grow capabilities across therapeutic areas. Management expects the expanded capabilities and global reach to help catalyze a larger number of successful clinical trials by improving translational models for candidate molecules. The company is based in San Diego, California. AnaBios is a San Diego–based biotechnology company that advances drug development through its proprietary Phase X technology. The company focuses on therapeutic areas with major unmet need, including pain, cardiac disease and neurodegenerative diseases. Its technology can generate human-relevant preclinical data with the potential to assess drug safety and reduce clinical-stage failures. AnaBios offers drug discovery services to major pharmaceutical companies in the USA, Europe, Japan and Korea while also conducting its own drug discovery in pain and heart disease. The company is led by CEO Andre Ghetti, Ph.D., and intends to use new funding to expand contract research capabilities and accelerate its internal drug programs. AnaBios is a contract research organization based in San Diego that deploys assays and develops databases to assess drug efficacy and safety. Its platform is designed to provide relevant data in advance of clinical trials, enabling better decision making on compound selection, dosing, and risk mitigation. The company will use its assays and databases to inform preclinical-to-clinical decision processes for drug developers. AnaBios is led by CEO and Chairman Dr. Jack A. Reynolds. Financially, the company has begun Series A fundraising and intends to raise up to $2 million. It plans to use proceeds to fund a new laboratory facility in San Diego.

Total raised

$15M

Funding rounds

4

Latest round

Equity

Latest activity

Dec 2016